

Longjumeau, February 6, 2014

<i>(in thousands of euros)</i>	2012 published (including SBS)	2012 restated (without SBS)	2013	% change
Total as of 31 December	174 289	171 128	164 900	-3,6%
<i>including Pharmaceutical Synthesis</i>	<i>110 001</i>	<i>109 758</i>	<i>107 693</i>	<i>-1,9%</i>
<i>including Fine Specialty Chemicals</i>	<i>64 288</i>	<i>61 370</i>	<i>57 207</i>	<i>-6,8%</i>

The sale of SBS was finalized on March 20, 2013.

The consolidated net sales of the PCAS Group in 2013 were down 3.6% compared to 2012, showing a substantial decline in sales in the fourth quarter of 2013.

Pharmaceutical Synthesis

Pharmaceutical Synthesis activities, affected by the planned slowdown of a contract, posted a slight fall (1.9%), whereas the patented molecule activity showed very satisfactory growth throughout the year, while the generics activity slowed down in the fourth quarter.

Fine Specialty Chemicals

Fine Specialty Chemicals activities posted a 6.8% fall, reflecting shrinking demand more particularly on European markets regarding New Technologies segment, whereas Performance

Chemicals and Fragrance-Flavors-Cosmetics activities showed continued growth over the period.

Consequently, the Group's Current Operating Income will be lower in 2013 compared to 2012, but its Net Income should be higher in 2013 than in 2012.

Next date :

2013 results, on February 20, 2014

About PCAS:

Founded in 1962, PCAS is an international fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability. PCAS also develops ranges of proprietary products based on intellectual property.